Diclofenac Solofarm eye drops 0.1%, 5ml

• Inhibition of miosis during cataract surgery (the drug does not have mydriatic properties and does not replace standard drugs that cause pupil dilation);

• treatment and prevention of inflammatory processes after eye surgery;

• prevention of cystic macular edema after cataract surgery;

• treatment of non-infectious conjunctivitis;

• treatment and prevention of post-traumatic inflammatory process with penetrating and non-penetrating wounds of the eyeball (as an addition to local antibacterial therapy).

Locally.

To inhibit intraoperative miosis, the drug is instilled into the conjunctival sac for 2 hours at intervals of 30 minutes (4 times) before the operation.

For the prevention of cystic edema of the macula, the drug is instilled 1 drop 3 times a day for 2-3 weeks after the operation.

For the treatment of post-traumatic inflammatory process with non-penetrating injuries of the eyeball, 1 drop is instilled for 4-6 hours.

The duration of treatment is determined by the doctor, depending on the course of the disease and the needs of the patient. For example, to reduce the severity of pain after eye surgery (after refractive surgery), the drug should be instilled 1-2 drops per hour before surgery, 1-2 drops in the first 15 minutes after surgery and 1 drop every 4-6 hours within 3 days after the operation.

Other indications: 1 drop 3-4 times a day, depending on the severity of the condition. The course of treatment can last from 1 to 2 weeks.

How to work with a dropper tube:

1. Separate one dropper tube, put the rest back in the package.

2. Open the dropper tube (making sure that the solution is in the lower part of the dropper tube, turn and separate the valve with rotating movements).

3. Drop the required amount of the drug into the eyes.

4. Close the dropper tube with a valve. The opened dropper tube can be stored for no more than 24 hours, then the dropper tube should be discarded.

1 ml of the drug contains:

Active ingredient: Diclofenac sodium - 1.0 mg

Excipients: Benzalkonium chloride - 0.05 mg Hydroxypropylbetadex - 20.0 mg Propylene glycol - 15.0 mg Boric acid - 4.8 mg Sodium tetraborate decahydrate (borax) - 0.4 mg Disodium edetate (Trilon B) - 0.1 mg Water for injection - up to 1 ml

• Hypersensitivity to drug components,

• violation of hematopoiesis of unknown origin,

• erosive and ulcerative processes in the gastrointestinal tract in the stage of exacerbation.

• Like other non-steroidal anti-inflammatory drugs (NSAIDs), the drug is contraindicated in patients with attacks of bronchial asthma, urticaria, acute rhinitis associated with the use of acetylsalicylic acid or other drugs that inhibit the activity of prostaglandin synthetase. There is a possibility of cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives and other NSAIDs.

• Intraocular use of the drug during surgical procedures is contraindicated.

  With care: Epithelial herpetic keratitis (including a history); diseases that cause bleeding disorders (including hemophilia, prolonged bleeding time, tendency to bleed); bronchial asthma caused by the intake of acetylsalicylic acid; elderly age.

Pharmacodynamics:

Diclofenac is a phenylacetic acid derivative that has anti-inflammatory and analgesic effects. The mechanism of action is due to the indiscriminate inhibition of the activity of cyclooxygenase 1 and 2, which leads to the suppression of the synthesis of prostaglandins in the focus of inflammation. When applied topically in the form of eye drops, diclofenac reduces eye inflammation resulting from infection, injury, or surgery; reduces miosis during surgical operations, reduces the synthesis of prostaglandins in the moisture of the anterior chamber.

Pharmacokinetics:

The maximum concentration of the substance in the cornea and in the conjunctiva is reached by 30 minutes after instillation. The drug is rapidly excreted from the body, complete elimination is observed after 6 hours. The drug enters the anterior chamber of the eye; does not enter the systemic circulation in therapeutically significant concentrations.

Side effects

Often: temporary mild to moderate eye irritation. Infrequently: itching in the eyes, conjunctival hyperemia and blurred vision (immediately after instillation). Rarely: punctate keratitis or corneal lesions (after repeated use of the drug). In patients at risk of developing corneal lesions, for example, when using glucocorticosteroids or as a result of various diseases (infections, rheumatoid arthritis), with repeated use of the drug in rare cases, it is possible to develop complications that threaten vision: ulcerative or punctate keratitis, corneal epithelial defects, edema and thinning cornea. Very rare: shortness of breath and worsening of the course of bronchial asthma, pain in the eyes. Allergic reactions Rarely: conjunctival hyperemia, allergic conjunctivitis, redness, itching and swelling of the eyelids, urticaria, rash, eczema, erythema, pruritus,hypersensitivity, cough and rhinitis.

Interaction

Instillation into the conjunctival cavity of NSAIDs, including diclofenac, together with glucocorticosteroids (GCS) in patients with severe corneal inflammation can lead to the progression of corneal lesions. Care should be taken when using the drug together with GCS in patients with severe corneal inflammation. If necessary, it can be used simultaneously with other eye drops, including those containing GCS. In this case, the break between instillations should be at least 5 minutes to prevent the washing out of the active substances by subsequent doses.